Excitability and gap junction-mediated mechanisms in nucleus accumbens regulate self-stimulation reward in rats.
The nucleus accumbens (Acb) is a part of the striatum which integrates information from cortical and limbic brain structures, and mediates behaviors which reinforce reward. Previous work has suggested that neuronal synchrony mediated by gap junctions in Acb-related areas is involved in brain pleasure and reward. In order to gain insight into functional aspects of the neural information processing at the level of the striatum, we explored the possible role of Acb gap junctional communication and chemical synapses on reward self-stimulation in rats using positive reinforcement. Rats were trained to press a lever that caused an electrical current to be delivered into the hypothalamus, which is recognized to cause pleasure/reward. Intracerebral infusion into the Acb of the gap junctional blocker carbenoxolone (CBX) decreased the lever-pressing activity. Considering that the net effect of blocking gap junctions is a reduced synchronized output of the cellular activities, which at some level represents a decrease in excitability, two other inhibitors of neuronal excitability, carbamazepine (CBZ) and tetrodotoxin (TTX), were infused into the Acb and their effects on lever-pressing assessed. All manipulations that diminished excitability in the Acb resulted in reduced lever-pressing activity. CBX and TTX were also infused into motor cortex mediating forelimb lever-pressing with no effect. However, a manipulation that has the net effect of increasing excitation, the infusion of the opiate antagonist naloxone, also decreased significantly brain self-stimulation. We conclude that reward behaviors depend to a great extent on both excitability and gap junction-mediated mechanisms in Acb neuronal networks. Thus, the Acb provides a site for the study of pleasure/reward, addiction and conscious experience.
Kokarovtseva
L
L
Neuroscience and Mental Health Programme and Brain and Behaviour Centre, Division of Neurology, Hospital for Sick Children, Toronto, Ontario, Canada M5G1X8.
Jaciw-Zurakiwsky
T
T
Mendizabal Arbocco
R
R
Frantseva
M V
MV
Perez Velazquez
J L
JL
D000818:Animals; D002220:Carbamazepine / Q000008:administration & dosage; D002229:Carbenoxolone / Q000008:administration & dosage; D002491:Central Nervous System Agents / Q000008:administration & dosage; D004558:Electric Stimulation; D017629:Gap Junctions / Q000187:drug effects / Q000502:physiology*; D007031:Hypothalamus / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009044:Motor Cortex / Q000187:drug effects; D009270:Naloxone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D012054:Reinforcement, Psychology; D012201:Reward; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D026941:Sodium Channel Blockers / Q000008:administration & dosage; D013779:Tetrodotoxin / Q000008:administration & dosage
D002491:Central Nervous System Agents; D009292:Narcotic Antagonists; D026941:Sodium Channel Blockers; D002220:Carbamazepine; D009270:Naloxone; D013779:Tetrodotoxin; D002229:Carbenoxolone